Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other EventsItem 8.01 Other Events.
On September6, 2018, Supernus Pharmaceuticals,Inc. issued a press release announcing that the United States Court of Appeals for the Federal Circuit affirmed the New Jersey District Court’s decision that TWi Pharmaceuticals,Inc. and its subsidiary infringed three Oxtellar XR® Orange Book patents and that all three patents are valid. A copy of this press release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
The following document is furnished as an Exhibit to Item 8.01 hereof:
Exhibit99.1 — Press Release Dated September6, 2018.
SUPERNUS PHARMACEUTICALS INC ExhibitEX-99.1 2 a18-27098_1ex99d1.htm EX-99.1 Exhibit 99.1 Supernus Wins Appeal on Oxtellar XR® against TWi Second Appeal Win against Generic Filers ROCKVILLE,…To view the full exhibit click
About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
An ad to help with our costs